Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities

Despite the implication of vascular endothelial growth factor-A (VEGF-A) in the pathophysiology of uveal melanoma (UM), the anti-VEGF-A antibody bevacizumab yielded conflicting results on UM growth. Here, we evaluated whether bevacizumab and ranibizumab, a humanized Fab-fragment against VEGF-A, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Tura, Aysegül, Pawlik, Vera E., Rudolf, Martin, Ernesti, Justus S., Stutzer, Jan-Niklas, Grisanti, Salvatore, Ranjbar, Mahdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628228/
https://www.ncbi.nlm.nih.gov/pubmed/31234419
http://dx.doi.org/10.3390/cancers11060868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628228/
https://www.ncbi.nlm.nih.gov/pubmed/31234419
http://dx.doi.org/10.3390/cancers11060868

Ejemplares similares